Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel.
Chemotherapy with docetaxel remains the standard first-line treatment in patients with castration-resistant prostate cancer (CRPC). To date there is no recommended second-line therapy in case of progression after docetaxel treatment. Knowledge of the molecular and cellular changes that occur during the transition of hormone-native to CRPC is increasing rapidly opening new therapy strategies in CRPC patients. This article will focus on recent available therapy options for patients with progressive CRPC after first-line treatment with docetaxel and highlights promising novel substances that are currently under investigation.
Arsov
Christian
C
Department of Urology, Heinrich-Heine University of Düsseldorf, Düsseldorf, Germany. christian.arsov@med.uni-duesseldorf.de
Winter
Christian
C
Rabenalt
Robert
R
Albers
Peter
P
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016879:Salvage Therapy / Q000379:methods*; D043823:Taxoids / Q000627:therapeutic use
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel